Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Bortezomib and Vorinostat Therapy as Maintenance Therapy after Autologous Transplant for Multiple Myeloma.

Holmberg LA, Green D, Libby E, Becker PS.

Acta Haematol. 2019 Aug 21:1-9. doi: 10.1159/000501298. [Epub ahead of print]

PMID:
31434076
2.

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.

Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang ES.

Blood Adv. 2019 Jul 9;3(13):1939-1949. doi: 10.1182/bloodadvances.2019030916.

3.

Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes.

Hsu J, Reilly A, Hayes BJ, Clough CA, Konnick EQ, Torok-Storb B, Gulsuner S, Wu D, Becker PS, Keel SB, Abkowitz JL, Doulatov S.

Blood. 2019 Jul 11;134(2):186-198. doi: 10.1182/blood.2018884338. Epub 2019 Apr 22.

PMID:
31010849
4.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.

5.

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A.

Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.

6.

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2019 Apr;60(4):1023-1029. doi: 10.1080/10428194.2018.1516036. Epub 2018 Oct 2.

PMID:
30277112
7.

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.

Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R.

Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.

8.

Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A.

Adair JE, Chandrasekaran D, Sghia-Hughes G, Haworth KG, Woolfrey AE, Burroughs LM, Choi GY, Becker PS, Kiem HP.

Haematologica. 2018 Nov;103(11):1806-1814. doi: 10.3324/haematol.2018.194571. Epub 2018 Jul 5.

9.

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.

10.

Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.

Cowan AJ, Stevenson PA, Libby EN, Becker PS, Coffey DG, Green DJ, Hyun TS, Fromm JR, Gopal AK, Holmberg LA.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1386-1391. doi: 10.1016/j.bbmt.2018.02.017. Epub 2018 Mar 1.

11.

Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD.

Cassaday RD, Stevenson PA, Wood BL, Becker PS, Hendrie PC, Sandmaier BM, Radich JL, Shustov AR.

Am J Hematol. 2018 Aug;93(4):546-552. doi: 10.1002/ajh.25030. Epub 2018 Jan 27.

12.

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.

Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, Becker PS.

Nat Commun. 2018 Jan 3;9(1):42. doi: 10.1038/s41467-017-02465-5.

13.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma.

Green DJ, Maloney DG, Storer BE, Sandmaier BM, Holmberg LA, Becker PS, Fang M, Martin PJ, Georges GE, Bouvier ME, Storb R, Mielcarek M.

Blood Adv. 2017 Nov 9;1(24):2247-2256. doi: 10.1182/bloodadvances.2017010686. eCollection 2017 Nov 14.

14.

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.

15.

Controversies Regarding Use of Myeloid Growth Factors in Leukemia.

Poston JN, Becker PS.

J Natl Compr Canc Netw. 2017 Dec;15(12):1551-1557. doi: 10.6004/jnccn.2017.7044. Review.

PMID:
29223992
16.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L.

J Natl Compr Canc Netw. 2017 Dec;15(12):1520-1541. doi: 10.6004/jnccn.2017.0175.

PMID:
29223990
17.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

18.

Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?

Zhou Y, Wood BL, Walter RB, Becker PS, Percival ME, Bar M, Shaw C, Gardner K, Hendrie P, Abkowitz J, Appelbaum FR, Estey E.

Leukemia. 2017 Nov;31(11):2536-2537. doi: 10.1038/leu.2017.263. Epub 2017 Aug 18. No abstract available.

PMID:
28819284
19.

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.

Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J.

Br J Haematol. 2017 Sep;178(6):906-913. doi: 10.1111/bjh.14792. Epub 2017 Jun 14.

20.

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.

21.

Characterization of the novel HLA-B*49:39 allele identified in a German leukaemia patient.

Becker PSA, Lindner S, Kim-Wanner SZ, Bug G, Seidl C.

HLA. 2017 Jul;90(1):43-45. doi: 10.1111/tan.13015. Epub 2017 Mar 30.

PMID:
28371391
22.
23.

Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.

PMID:
28351184
24.

Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.

Ulrickson ML, Puri A, Lindstrom S, Cassaday RD, De Padova N, Becker PS.

Am J Hematol. 2017 May;92(5):E75-E77. doi: 10.1002/ajh.24696. Epub 2017 Mar 20. No abstract available.

25.

Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia.

Adair JE, Sevilla J, Heredia CD, Becker PS, Kiem HP, Bueren J.

Curr Gene Ther. 2017;16(5):338-348. doi: 10.2174/1566523217666170119113029. Review.

PMID:
28103787
26.

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.

Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.

Amyloid. 2016 Dec;23(4):254-259. Epub 2016 Nov 23.

27.

The novel HLA-C*15:103 is characterised by an amino acid substitution in the alpha 2 domain.

Becker PS, Paranikulangara P, Rettinger E, Bader P, Seidl C.

HLA. 2016 Nov;88(5):267-268. doi: 10.1111/tan.12897. Epub 2016 Sep 20.

PMID:
27647648
28.

Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Rengstl B, Schmid F, Weiser C, Döring C, Heinrich T, Warner K, Becker PS, Wistinghausen R, Kameh-Var S, Werling E, Billmeier A, Seidl C, Hartmann S, Abken H, Küppers R, Hansmann ML, Newrzela S.

Oncoimmunology. 2016 Mar 16;5(6):e1160186. doi: 10.1080/2162402X.2016.1160186. eCollection 2016 Jun.

29.

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.

Magenau J, Westervelt P, Khaled S, McGuirk J, Hari P, Eapen M, Becker PS, Parkin B, Braun T, Logan B, Wang H, Jagasia M, Rowley SD, Kim DD, Schechter T, Frey N, Scott B, Churay T, Lieland S, Forman S, Mineishi S.

Bone Marrow Transplant. 2017 Jan;52(1):59-65. doi: 10.1038/bmt.2016.188. Epub 2016 Jul 18.

30.

Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.

Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, Nicoud I, Dahlberg A, Bernstein ID, Appelbaum FR, Estey EH.

Lancet Haematol. 2016 Jul;3(7):e330-9. doi: 10.1016/S2352-3026(16)30023-0. Epub 2016 Jun 7.

PMID:
27374466
31.

The Role of Biosimilars.

Zelenetz AD, Becker PS.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):626-9.

PMID:
27226500
32.

A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma.

Becker PS, Gooley TA, Green DJ, Burwick N, Kim TY, Kojouri K, Inoue Y, Moore DJ, Nelli E, Dennie T, Bensinger WI.

Blood Cancer J. 2016 May 13;6:e422. doi: 10.1038/bcj.2016.31. No abstract available.

33.

Selection and expansion of natural killer cells for NK cell-based immunotherapy.

Becker PS, Suck G, Nowakowska P, Ullrich E, Seifried E, Bader P, Tonn T, Seidl C.

Cancer Immunol Immunother. 2016 Apr;65(4):477-84. doi: 10.1007/s00262-016-1792-y. Epub 2016 Jan 25. Review.

34.

A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer.

Blau CA, Ramirez AB, Blau S, Pritchard CC, Dorschner MO, Schmechel SC, Martins TJ, Mahen EM, Burton KA, Komashko VM, Radenbaugh AJ, Dougherty K, Thomas A, Miller CP, Annis J, Fromm JR, Song C, Chang E, Howard K, Austin S, Schmidt RA, Linenberger ML, Becker PS, Senecal FM, Mecham BH, Lee SI, Madan A, Ronen R, Dutkowski J, Heimfeld S, Wood BL, Stilwell JL, Kaldjian EP, Haussler D, Zhu J.

J Natl Compr Canc Netw. 2016 Jan;14(1):8-17.

35.

Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

Araki D, Othus M, Walter RB, Becker PS, Sandhu V, Estey EH.

Leuk Lymphoma. 2016 May;57(5):1205-7. doi: 10.3109/10428194.2015.1079316. Epub 2015 Dec 23. No abstract available.

PMID:
26694896
36.

Four amino acid exchanges located in the alpha-2 domain specify the novel HLA-B*50:20 allele.

Becker PS, Seifried E, Seidl C.

Tissue Antigens. 2015 Dec;86(6):453-5. doi: 10.1111/tan.12697.

PMID:
26593755
37.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.

Br J Haematol. 2016 Jan;172(2):238-45. doi: 10.1111/bjh.13829. Epub 2015 Nov 16.

PMID:
26568032
38.

A randomized study of melphalan 200 mg/m(2) vs 280 mg/m(2) as a preparative regimen for patients with multiple myeloma undergoing auto-SCT.

Bensinger WI, Becker PS, Gooley TA, Chauncey TR, Maloney DG, Gopal AK, Green DJ, Press OW, Lill M, Ifthikharuddin JJ, Vescio R, Holmberg LA, Phillips GL.

Bone Marrow Transplant. 2016 Jan;51(1):67-71. doi: 10.1038/bmt.2015.211. Epub 2015 Sep 14.

39.

Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.

JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.

40.

Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.

Fang M, Becker PS, Linenberger M, Eaton KD, Appelbaum FR, Dreyer Z, Airewele G, Redell M, Lopez-Terrada D, Patel A, Rabin KR, Lu X.

Am J Clin Pathol. 2015 Aug;144(2):263-70. doi: 10.1309/AJCPW83OXPYKPEEN.

PMID:
26185311
41.

JAK/STAT Pathway Inhibitors and Neurologic Toxicity: Above All Else Do No Harm?

Scott BL, Becker PS.

JAMA Oncol. 2015 Aug;1(5):651-2. doi: 10.1001/jamaoncol.2015.1591. No abstract available.

PMID:
26181358
42.

Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission.

Shadman M, Gopal AK, Kammerer B, Becker PS, Maloney DG, Pender B, Shustov AR, Press OW, Pagel JM.

Leuk Lymphoma. 2016;57(3):572-6. doi: 10.3109/10428194.2015.1067701. Epub 2015 Aug 28.

43.

Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid.

Loeb KR, Cherian S, Becker PS, Walter RB, Pagel JM, Abkowitz JL, Appelbaum FR, Wood BL, Estey EH.

Br J Haematol. 2016 Jan;172(1):134-6. doi: 10.1111/bjh.13465. Epub 2015 May 26. No abstract available.

PMID:
26010105
44.

Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration.

Huang JC, Basu SK, Zhao X, Chien S, Fang M, Oehler VG, Appelbaum FR, Becker PS.

Blood Cancer J. 2015 Apr 10;5:e302. doi: 10.1038/bcj.2015.17.

45.

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age.

Buckley SA, Mawad R, Gooley TA, Becker PS, Sandhu V, Hendrie P, Scott BL, Wood BL, Walter RB, Smith K, Dean C, Estey EH, Pagel JM.

Br J Haematol. 2015 Aug;170(3):349-55. doi: 10.1111/bjh.13437. Epub 2015 Apr 8.

PMID:
25854284
46.

Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.

Araki D, Othus M, Walter RB, Sandhu V, Sandmaier BM, Becker PS, Appelbaum FR, Estey EH.

Haematologica. 2015 Jul;100(7):e254-6. doi: 10.3324/haematol.2014.118570. Epub 2015 Mar 20. No abstract available.

47.

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.

Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, Sandhu VK, Abkowitz JL, Appelbaum FR, Estey EH.

J Clin Oncol. 2015 Apr 10;33(11):1258-64. doi: 10.1200/JCO.2014.58.3518. Epub 2015 Mar 2.

PMID:
25732155
48.

Idarubicin, cytarabine, and pravastatin as induction therapy for untreated acute myeloid leukemia and high-risk myelodysplastic syndrome.

Shadman M, Mawad R, Dean C, Chen TL, Shannon-Dorcy K, Sandhu V, Hendrie PC, Scott BL, Walter RB, Becker PS, Pagel JM, Estey EH.

Am J Hematol. 2015 Jun;90(6):483-6. doi: 10.1002/ajh.23981. Epub 2015 Feb 27.

49.

Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.

Chen X, Newell LF, Xie H, Walter RB, Pagel JM, Sandhu VK, Becker PS, Hendrie PC, Abkowitz JL, Appelbaum FR, Estey EH.

Leukemia. 2015 Aug;29(8):1779-80. doi: 10.1038/leu.2015.23. Epub 2015 Feb 4. No abstract available.

PMID:
25650090
50.

Sparse expression bases in cancer reveal tumor drivers.

Logsdon BA, Gentles AJ, Miller CP, Blau CA, Becker PS, Lee SI.

Nucleic Acids Res. 2015 Feb 18;43(3):1332-44. doi: 10.1093/nar/gku1290. Epub 2015 Jan 12.

Supplemental Content

Loading ...
Support Center